Drug Trial Radar · NCT02369861
Study of ST266 Eye Drops in Treating Dry Eye
Last checked: Nov 19, 2026Latest source record: May 13, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Mar 2015
Primary completion
Oct 2015
Study completion Dec 2015
Sponsor
- Lead sponsor
- Noveome Biotherapeutics, formerly StemnionIndustry
- Sponsor type
- Industry
- Collaborators
- U.S. Navy Bureau of Medicine
- First posted
- Feb 24, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Subjects with moderate-to-severe Dry Eye by symptoms will be screened including history, ophthalmic examination to include the status of their ocular structure and function and evaluation of tear production. Blood will be blood drawn for complete blood count and chemistry panel. They will also have a urinalysis and pregnancy test in women of child-bearing potential. Subjects will have a two week "run-in" period in which they use artificial tears. If their Dry Eye signs and symptoms do not improve significantly, they will be enrolled and will receive study drug. Safety evaluation includes assessment of the structure and function of the eyes including retina examination and corrected visual acuity. Subjects who meet the inclusion and exclusion criteria will be randomly assigned to one of two treatment arms, ST266 or "artificial tears" eye drops. The randomization scheme is 1:1 ST266:artificial tears. Subjects will self-administer their eye drops four times each day. Subjects will be seen in the office of the ophthalmologist/optometrist at baseline (week zero), one week, three weeks, six weeks and ten weeks. Eye examination will be done at each visit. The baseline eye tests and lab work will be repeated after the treatment phase of the study at the end of week six. Following 6 weeks of treatment, the subjects will be followed for 4 additional weeks.
Conditions
- Dry Eye Syndrome
Interventions
ST266Drug
Topical ocular application 4 times per day
Refresh Lubricant Eye DropsDrug
Topical ocular application 4 timer per day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Corneal staining with fluoresceinTime frame: Change in degree of staining at 6 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Price Vision Group
Indianapolis, Indiana
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.